TaiGen Biopharmaceuticals Holdings Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 19.14 million compared to TWD 2.36 million a year ago. Net income was TWD 10.79 million compared to net loss of TWD 141.62 million a year ago. Basic earnings per share from continuing operations was TWD 0.02 compared to basic loss per share from continuing operations of TWD 0.19 a year ago. Diluted earnings per share from continuing operations was TWD 0.02.
For the nine months, sales was TWD 31.51 million compared to TWD 1,292.99 million a year ago. Net loss was TWD 124.9 million compared to net income of TWD 915.18 million a year ago. Basic loss per share from continuing operations was TWD 0.17 compared to basic earnings per share from continuing operations of TWD 1.28 a year ago.